<DOC>
	<DOCNO>NCT00969462</DOCNO>
	<brief_summary>In previous study , investigator find patient Hodgkin 's lymphoma ( HL ) treat ABVD ( adriamycin , bleomycin , vinblastine decarbazine ) absence alopecia may predict poor response treatment [ complete remission ( CR ) rate 79 % versus 31 % , P &lt; 0.0005 , respectively ] . Also , patient without alopecia few episode either leucopenia , neutropenia , deferral treatment course number course dose reduction [ 88 % vs. 62.5 % , P=0.05 , presence least one ] . One explanation phenomenon relate low systemic exposure chemotherapeutic drug patient retain hair . There wide interpatient variability pharmacokinetic pharmacodynamic parameter doxorubicin systemic exposure degree myelosuppression . In pilot study 18 patient investigator could find previous association alopecia , response chemotherapy bone marrow depression . However , analyze doxorubicin pharmacokinetics , patient remission 2 fold low AUC ( area curve ) 3 fold low peak ( p=0.06 ) . The investigator ' lack approve previous finding might explain small study group .</brief_summary>
	<brief_title>Doxorubicin Pharmacokinetics Response Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Aim study : To evaluate association response chemotherapy , degree myelosuppression pharmacokinetics doxorubicin non-Hodgkin 's lymphoma ( NHL ) patient . Methods : Study protocol : 1 . At diagnosis Demographic clinical parameter collect ( Appendix 1 ) 2 . At course 2 : 1 . Doxorubicin give 5-7 minute infusion medication ( Doxorubicin dose collect ( Appendix 1 ) ) 2 . Blood sample course 2 , : 0 minute 30 minute 120 minute 24 hour Two 2ml EDT tube drawn time The tube centrifuge 3000 RPM 15 min . Plasma sample store - 700C 3 . At end chemotherapy course follow data collect ( Appendix 2 ) : 1 . Episodes bone marrow depression ( leucopenia , neutropenia ) Treatment delay Dose reduction Neutropenic fever 2 . Remission status [ Complete remission ( CR ) - disappearance clinical sign symptom NHL along normal laboratory radiological finding ] . 4 . At end one year CR Remission status Number patient : 30</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age â‰¥ 18 year Biopsy proven intermediate grade NHL No previous chemotherapy At least 4 course RCHOP maximal dos plan An informed consent Do meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Doxorubicin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>response</keyword>
	<keyword>association response chemotherapy</keyword>
	<keyword>myelosuppression degree</keyword>
	<keyword>doxorubicin pharmacokinetics</keyword>
</DOC>